CRISPR Therapeutics

114 articles with CRISPR Therapeutics

• 

  Despite One Patient Death, CRISPR Therapeutics' Off-the-Shelf CAR-T Shows Pro...

  10/21/2020

  Despite promising Phase I data for its CRISPR-based allogeneic CAR-T therapy, CRISPR Therapeutics may have a safety issue to contend with.

• CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies

  10/21/2020

  50% (2/4) complete response (CR)rate at three months in the Dose Level 3 (DL3)cohort; both respondersremain in CR

• CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry

  10/7/2020

  CRISPR Therapeutics (Nasdaq: CRSP), today announced Professor Emmanuelle Charpentier, CRISPR Therapeutics’ co-founder, has been awarded the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR/Cas9 system. Professor Charpentier co-founded CRISPR Therapeutics together with Rodger Novak and Shaun Foy. She is Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and

• CRISPR Therapeutics to Participate in Upcoming Investor Conferences - Sep 29, 2020

  9/29/2020

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in October:

• CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease

  9/22/2020

  CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Inco r porated  (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of severe sickle cell disease (SCD). PRIME is a regulatory mechanism that provides early and proactive supp

• CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

  9/3/2020

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020, at 11:20 a.m. ET. A live webcast of the event will be available on the "Eve

• CRISPR Therapeutics to Participate in Upcoming Investor Conferences - July 30, 2020

  7/30/2020

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in August

• CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results

  7/27/2020

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2020.

• CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares - July 01, 2020

  7/1/2020

  CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share.

• 

  Biopharma Companies Continue to Expand, Add Jobs Despite Ongoing Pandemic

  6/30/2020

  Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.

• CRISPR Therapeutics Announces Proposed Offering of Common Shares

  6/29/2020

  CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $325,000,000 of common shares.

• CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility

  6/25/2020

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it is building a new cell therapy manufacturing facility in Framingham, Massachusetts for clinical and commercial production of the Company’s investigational cell therapy product candidates.

• 

  Clinical Catch-Up: June 8-12

  6/15/2020

  It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
• 

  European Hematology Association Meeting Kicks Off with Strong Data Presentations

  6/12/2020

  Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.

• CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress

  6/12/2020

  CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia and severe sickle cell disease, and highlighted recent progress in the CTX001 development program.

• CRISPR Therapeutics to Participate in Upcoming Investor Conferences

  5/26/2020

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in June: Jefferies Global Healthcare Conference Date: Tuesday, June 2, 2020 Fireside chat: 1:30 p.m. ET Goldman Sachs 41st Annual Global Heal

• CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting

  5/15/2020

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that four abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will take place from June 22 to 24, 2020. Session information is available online via the Annual Meeting Itinerary

• New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress

  5/14/2020

  CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new data from two ongoing Phase 1/2 clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001 in severe hemoglobinopathies have been accepted for an oral presentation at the EHA Congress, which will take place virtually from June 11-14, 2020. 

• CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies

  5/11/2020

  CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia

• CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference

  5/7/2020

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the virtual Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020, at 11:40 a.m. ET. A live webcast of the fireside chat will be avail